Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism

The development of antitumor chemotherapy drugs remains a key goal for oncologists, and natural products provide a vast resource for anti-cancer drug discovery. In the current study, we found that the flavonoid dihydromyricetin (DHM) exhibited antitumor activity against liver cancer cells, including...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zhang, Qingyu, Liu, Jie, Liu, Bin, Xia, Juan, Chen, Nianping, Chen, Xiaofeng, Cao, Yi, Zhang, Chen, Lu, CaiJie, Li, Mingyi, Zhu, Runzhi
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3982169/
https://ncbi.nlm.nih.gov/pubmed/24717393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep04628
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars